Lv31
230 积分 2024-03-04 加入
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
28天前
已完结
Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin)
28天前
已完结
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
1个月前
已完结
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
2个月前
已完结
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
2个月前
已完结
间质性肺病多学科讨论规范中国专家共识
2个月前
已完结
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
3个月前
已完结
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
4个月前
已完结
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy
5个月前
已完结
皖公网安备34019202002308
